| Literature DB >> 32560510 |
Jessica B Lewis1, Sonya S Brady2, Siobhan Sutcliffe3, Ariana L Smith4, Elizabeth R Mueller5, Kyle Rudser6, Alayne D Markland7, Ann Stapleton8, Sheila Gahagan9, Shayna D Cunningham10.
Abstract
Lower urinary tract symptoms affect a substantial number of women in the United States (U.S.) and globally. In 2015, the Prevention of Lower Urinary tract Symptoms in women (PLUS) Research Consortium was funded to establish the scientific basis for prevention efforts by (1) understanding healthy bladder function and (2) identifying risk and protective factors for bladder health in women across the lifecourse. This transdisciplinary consortium generated a list of over 600 candidate risk and protective factors for bladder health in women and girls and refined and prioritized these into 29 focused research questions to inform a national longitudinal observational study in the U.S. This paper describes that process using design thinking, a human-centered set of principles and strategies by which innovations are developed, as a framework. Design thinking is an iterative process consisting of five stages: Empathizing with end-users of innovations, Defining core principles girding the work, Ideation of all possible solutions, and rapid-cycle Prototyping and Testing of solutions. Lessons learned are offered to inform future prevention science research endeavors that might benefit from such an approach.Entities:
Keywords: bladder health; design thinking; lower urinary tract symptom; prevention; public health; research question development; transdisciplinary; women
Mesh:
Year: 2020 PMID: 32560510 PMCID: PMC7345219 DOI: 10.3390/ijerph17124340
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Prevention of Lower Urinary tract Symptoms (PLUS) Conceptual Framework adapted from Glass and McAtee (2006); published in Brady et al. (2018).
Figure 2Stages of the design thinking process.
Figure 3PLUS Consortium research themes.
Prioritization considerations for research questions.
|
| 1. Does the research question involve a modifiable factor (i.e., does it inform prevention)? |
| 2. If the research question relates to a modifiable factor, would the associated intervention be easy to implement/well-accepted? Low cost? | |
| 3. Does the research question inform groups more or less susceptible to the influence of a particular risk or protective factor (i.e., effect modification)? | |
| 4. Does the research question involve a risk or protective factor with a high prevalence | |
| 5. Does the research question have the potential for policy level impact? | |
| 6. Is the research question timely? | |
| 7. Does the research question relate to a risk/protective factor specific to bladder health | |
| 8. Does the research question help us understand women’s health, health behaviors, and health decision-making more broadly (i.e., does it have implications beyond bladder health?)? | |
| 9. Is the research question supported by a plausible mechanism (e.g., biological, psychological, etc.)? | |
| 10. Does the research question address a novel risk/protective factor? | |
| 11. Does the research question provide confirmatory data for a less well-established factor? | |
| 12. Does the research question provide confirmatory data for a more well-established factor? | |
| 13. Is the research question important enough that any result (positive, inverse, null) will move the field forward? | |
| 14. Could the research question push the field into new directions of inquiry or novel areas of research? | |
| 15. Is the research question well-positioned for the uniqueness of the consortium, or is it better suited to an individual research group or to existing data/ongoing studies? | |
| 16. Does the research exemplify transdisciplinary science? | |
|
| 17. Can the research question be addressed in a sample of the general population or does it require recruitment of a specific population? |
| 18. How many constructs are needed to answer the research question? | |
| 19. What is the degree of invasiveness of assessment of each construct (e.g., self-report, physical examination, recall/real-time assessment)? | |
| 20. What is the length of time/number of items needed to address each construct? | |
| 21. Do any of the necessary constructs contribute to answering more than one research question? | |
| 22. Does the research question overlap with multiple themes? | |
| 23. Will the research question provide preliminary data for additional grants/pilot projects? | |
|
Do the questions address all levels of our conceptual framework? Do the questions address the full life course? | |
Lessons learned: Sequence of activities and proposed revisions for future research.
|
|
|
| |
|
| 7/15- | PLUS investigators bring diverse clinical/community experience | |
| 7/15- | Remote calls and in-person meetings with transdisciplinary investigators | ||
| 9/15- | Webinars share transdisciplinary knowledge and perspectives | ||
| 9/15 | Myers–Briggs type sharing | ||
| 7/17–4/18 | SHARE Qualitative Study | This activity would have been more helpful to begin earlier. It began during Prototyping and Testing, requiring revisiting of measures. A broad community engagement process early in this phase would have been preferable. | |
|
| 7/15 | U.S. National Institute of Diabetes and Digestive and Kidney Diseases defines inclusion in PLUS | |
| 9/15–7/17 | PLUS develops research definition of bladder health | ||
| 7/15–9/15 | PLUS establishes conceptual framework | ||
|
| 9/16–10/16 | Terminology, Conceptual Frameworks and Models (TCFM) sub-committee generates list of candidate risk and protective factors | |
| 11/15 | Consortium participates in sticky notes ideation exercise: 600 factors identified | This could have preceded the TCFM generation of factors. | |
| 11/15–12/15 | TCFM refines list of factors | ||
| 1/16–2/16 | Members rank top 20 determinants; 44 prioritized factors across 8 themes | ||
|
| 1/17–7/17 | Individual and Environmental Work Groups develop measures for risk/protective factors | Consensus on a process to formulate research questions and measure of risk and protective factors at the Define stage would have prevented shifting directions. |
| 8/17–6/18 | Theme Teams develop research questions | Consensus on a plan to determine key covariates would have prevented investigators from trying to incorporate key covariates into questions to ensure their inclusion, leading to more novel questions. | |
| 10/17 and 11/17 | Theme Teams present research questions to entire consortium for comment | ||
| 11/17 | Study Design and Methodology Group (1) defines criteria to prioritize research questions and (2) gathers consortium feedback about which scientific and practical considerations are most important for prioritization | It would have been helpful at the Define stage for the PLUS Consortium to have determined the scientific and practical considerations of greatest importance to the consortium. These criteria could have been used to prioritize and select risk and protective factors and research questions of highest importance efficiently through a transparent and objective process. | |
| 4/18–2/19 | PLUS reviews 27 questions and generates and prioritizes missing questions in a similar manner | ||
| 2/19 | PLUS adopts 29 research questions for refinement and use in a national longitudinal observational study |